EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study

Zhijuan Du, Xiangwei Ge, Yao Li, Yuhui Qin, Hao Fan, Yahui Lv, Xiangyu Du, Zhefeng Liu iD

Postgraduate Medical Journal · 2025

DOI: 10.1093/postmj/qgaf045 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Postgraduate Medical Journal, 2025. Verfasst von Zhijuan Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Haidian District, 28 Fuxing Road, Beijing, 100853, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy has shown long-term benefits in advanced nonsmall cell lung cancer patients. However, the clinical characteristics, prognosis, and selection of appropriate therapies for long-term responders (LTR) to first-line programmed cell death protein-1/programmed cell death ligand-1 (PD-L1) inhibitors remain undetermined.

Methods

About 413 advanced nonsmall cell lung cancer patients were included from 1 June 2015 to 31 August 2021. It examined clinicopathologic data, overall survival distributions, and treatment strategies involving immune checkpoint inhibitors.

Results

Among the patients, 213 (51.6%) were LTRs. PD-L1 expression ≥50% was observed in 39.1% of LTR patients, higher than in non-LTR patients (21.7%). After propensity score matching, Cox univariable analysis revealed pathological type (hazard ratio [HR] 0.563; 95% confidence interval [CI]: 0.391–0.811; P = .002), bone metastasis (HR 1.820; 95% CI: 1.278–2.590; P = .001), and liver metastasis (HR 2.220; 95% CI: 1.291–3.817; P = .004) as significant predictors of LTR. The pathological type (HR 0.641; 95% CI: 0.441–0.932; P = .020), bone metastasis (HR 1.593; 95% CI: 1.106–2.293; P = .012), and liver metastasis (HR 1.820; 95% CI: 1.046–3.165; P = .034) were significant predictors of LTR in Cox multivariable analysis. Significant difference showed in overall survival (P < .0001) for Pembrolizumab-chemotherapy of lung squamous cell carcinoma in LTR group compared with Sintilimab-chemotherapy.

Conclusions

Nonsquamous cell carcinoma, bone metastasis, and liver metastasis were significant predictors of LTR. LTR patients showed a higher proportion of PD-L1 expression. Compared to Sintilimab-chemotherapy, Pembrolizumab-chemotherapy may be more promising for long-term survival of lung squamous cell carcinoma patients. Key messages What is already known on this topic — Immunotherapy (IO) has demonstrated long-term survival benefits in advanced nonsmall cell lung cancer (NSCLC). However, the clinical characteristics, prognosis, and optimal treatment strategies for long-term responders (LTR) to first-line programmed cell death protein-1/programmed cell death ligand-1 inhibitors remain unclear, necessitating further investigation. What this study adds — This study identifies nonsquamous cell carcinoma, absence of bone metastasis, and absence of liver metastasis as significant predictors of LTR in NSCLC patients. LTR patients exhibit a higher proportion of programmed cell death ligand-1 expression (≥50%). Additionally, Pembrolizumab-chemotherapy shows superior overall survival outcomes for LTR with lung squamous cell carcinoma compared to Sintilimab-chemotherapy. How this study might affect research, practice, or policy — These findings provide critical insights for patient stratification and therapy optimization in NSCLC. The identification of predictive factors and superior therapeutic combinations can guide clinical decision-making, personalized treatment strategies, and inform future research on IO in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenHumansMaleFemaleRetrospective StudiesMiddle AgedAgedProgrammed Cell Death 1 ReceptorTreatment OutcomePrognosisAdult

Stichwörter der Autor:innen

PD-1/PD-L1 inhibitorsPembrolizumabimmunotherapylong-term responsenonsmall cell lung cancer

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, human

Autor:innen und Institutionen

  • Medical School of Chinese PLA, Haidian District, 28 Fuxing Road, Beijing, 100853, China.
  • Department of Medical Oncology, The First Medical Center of Chinese PLA General Hospital, Haidian District, 28 Fuxing Road, Beijing, 100853, China.
  • Department of Medical Oncology, Senior Department of Oncology, Fengtai District, The Fifth Medical Center of PLA General Hospital, No. 100, West Fourth Ring Middle Road, Beijing, 100039, China.

ORCID-Profile: Zhefeng Liu

Zitieren

APA

Du, Z., Ge, X., Li, Y., Qin, Y., Fan, H., Lv, Y., Du, X., & Liu, Z. (2025). Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf045

Vancouver

Du Z, Ge X, Li Y, Qin Y, Fan H, Lv Y, et al. Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study. Postgraduate Medical Journal. 2025. doi:10.1093/postmj/qgaf045

BibTeX
@article{Du2025,
  author = {Du, Zhijuan and Ge, Xiangwei and Li, Yao and Qin, Yuhui and Fan, Hao and Lv, Yahui and Du, Xiangyu and Liu, Zhefeng},
  title = {Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study},
  journal = {Postgraduate Medical Journal},
  year = {2025},
  doi = {10.1093/postmj/qgaf045}
}
Kostenlos starten →